S4-27.2 – Abstract session – NAFLD: Therapy

S4-27.2 - Abstract session - NAFLD: Therapy
This conversation with Ian Rowe, Jörn Schattenberg and Roger Green continues to unpack the rich EASL Congress 2023 program by discussing abstracts and presentations of interest. The group dives deep into liver science with commentary around emerging developments in NAFLD/NASH therapeutics.

Surfing NASH extends its preview coverage of the upcoming EASL Congress with a three-part episode. This conversation continues to unpack the 2023 program with Ian Rowe, Jörn Schattenberg and Roger Green.

Jörn begins by pointing to the Abstract session – NAFLD: Therapy which commences at 8:30 CEST on Friday morning. Specifically, he goes on to more closely detail a presentation related to time-restrictive eating which spurs an anecdote from Roger. Following, Ian describes what he finds fascinating about the opening presentation of this session concerning a Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with nonalcoholic fatty liver disease. This leads the group to comment on the influence of dual agonists in the wider landscape of drug development. The rest of the conversation considers the latest of what Roger presages to be a “fascinating set of advances” in the context of emerging individualized therapies by way of miRNA coupled with CAR-T to target fibrosis. In closing, Ian makes a point around “the amount of work that’s going to be required if and when a drug is licensed.” Listen on to hear his thoughts.

The world’s largest liver meeting takes place 21-24 June in Vienna with an international faculty of experts from over 200 institutions. The diverse program will feature 2500 abstracts and be a uniquely momentous occasion for developing multidisciplinary approaches aimed at putting a major dent in Fatty Liver disease. Stay tuned for more coverage and if you have any question or interests around the event, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Today’s episode is sponsored by HistoIndex, the first global company to provide stain-free, fully automated imaging solutions for visualizing and quantifying morphological and architectural features of fibrosis. HistoIndex couples breakthrough biophotonic technology with an AI-powered digital pathology system to provide consistent, high-throughput imaging in liver disease and cancer. The platform benefits clinical research and speeds development of drugs and diagnostics. For more information, visit www.histoindex.com.

Stay Safe and Surf On!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Sponsoring Partnerships!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.